Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.
FIG. 4

FIG. 4. From: Novel Discriminative Stimulus Effects of TPA023B, Subtype-Selective ?-aminobutyric-acidA/Benzodiazepine Modulator: Comparisons with Zolpidem, Lorazepam, and TPA023.

Results of generalization testing with vehicle (V) and TPA023B in groups of rats trained to discriminate zolpidem, lorazepam, or TPA023. Other details as in Figure 3.

Stephen J. Kohut, et al. Pharmacol Biochem Behav. ;90(1):65-73.
2.
FIG. 6

FIG. 6. From: Novel Discriminative Stimulus Effects of TPA023B, Subtype-Selective ?-aminobutyric-acidA/Benzodiazepine Modulator: Comparisons with Zolpidem, Lorazepam, and TPA023.

Mean number of times a rat’s paw slipped between the bars of the operant testing chamber 120-min following vehicle and 32 mg/kg TPA023B for the rats in the TPA023B training group. Brackets indicate SEM. *p<.05 by paired t test.

Stephen J. Kohut, et al. Pharmacol Biochem Behav. ;90(1):65-73.
3.
FIG. 1

FIG. 1. From: Novel Discriminative Stimulus Effects of TPA023B, Subtype-Selective ?-aminobutyric-acidA/Benzodiazepine Modulator: Comparisons with Zolpidem, Lorazepam, and TPA023.

Structures of TPA023 (Atack et al., 2006) and TPA0232B (compound 11, Russell et al., 2006) and their efficacies in modulation of GABA at cloned human GABAA receptor αxβ3γ2 subtypes. Efficacy values are expressed relative to the non-selective full agonist chlordiazepoxide (CDP). Note: Human and rat affinity and efficacy data with BZ ligands tend to be comparable (Hadingham et al., 1993).

Stephen J. Kohut, et al. Pharmacol Biochem Behav. ;90(1):65-73.
4.
FIG. 5

FIG. 5. From: Novel Discriminative Stimulus Effects of TPA023B, Subtype-Selective ?-aminobutyric-acidA/Benzodiazepine Modulator: Comparisons with Zolpidem, Lorazepam, and TPA023.

Mean training sessions to reach the training performance criterion for rats in the zolpidem-2.0-mg/kg, lorazepam-1.0 -mg/kg, and TPA023-1.0-mg/kg training groups after novel dose tests with their own training drug (Panel A), and after test sessions in which doses of 0.32, 1.0, 3.2, 10, and 32 mg/kg TPA023B had been administered (Panel B). Brackets indicate SEM. Note: The lowest novel test dose of TPA023 (0.032 mg/kg) is not shown in that training group in order to maintain consistency between the different training groups.

Stephen J. Kohut, et al. Pharmacol Biochem Behav. ;90(1):65-73.
5.
FIG. 2

FIG. 2. From: Novel Discriminative Stimulus Effects of TPA023B, Subtype-Selective ?-aminobutyric-acidA/Benzodiazepine Modulator: Comparisons with Zolpidem, Lorazepam, and TPA023.

Mean training sessions to reach the performance criterion for rats in the zolpidem-2.0-mg/kg, lorazepam-1.0 -mg/kg, and TPA023-1.0-mg/kg training groups. Assessment began with the first session in which D and ND sessions began alternating after FR 10 had been reached, and ended with the last session that met criterion prior to the back-to-back test sessions with the training drug dose and its vehicle, that defined demonstration of stimulus control by the training drug. Brackets indicate the SEM. The rats in the TPA023B group (3.2 - 18 mg/kg doses) did not meet the training performance criterion after 160 sessions, and training ended.

Stephen J. Kohut, et al. Pharmacol Biochem Behav. ;90(1):65-73.
6.
FIG. 3

FIG. 3. From: Novel Discriminative Stimulus Effects of TPA023B, Subtype-Selective ?-aminobutyric-acidA/Benzodiazepine Modulator: Comparisons with Zolpidem, Lorazepam, and TPA023.

Upper panels show mean percentages of responding on the training-drug-appropriate lever in test sessions after vehicle (V) and doses of zolpidem, lorazepam, or TPA023 for each training group, respectively. Connected points indicate the group mean, and unconnected points present data for individual rats; different symbols represent different rats. Dotted line indicates ED50 for each training dose. Lower panels show the overall mean rate of responding (i.e., on both levers combined) in the same test sessions. Dotted line indicates 50% reduction in rate of responding from the V mean.

Stephen J. Kohut, et al. Pharmacol Biochem Behav. ;90(1):65-73.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk